May 26 (UPI) -- U.S. biotechnology company Novavax says it has entered clinical trials for a potential coronavirus vaccine, with first results expected within weeks.
The "NVX‑CoV2373" vaccine candidate has begun a combined Phase I/II preliminary immunogenicity and safety trial, Novavax announced Monday.